The FDA found that MEDVi's website displayed compounded semaglutide and tirzepatide products with "MEDVi" on the label, which under FDA rules implies MEDVi itself is the manufacturer/compounder. According to the agency, that isn't accurate — MEDVi is not the entity actually compounding the drugs. The FDA classified this as a misbranding violation.
https://slimchecker.com/cheapest-glp1-without-insurance/ |